Diagnostic evaluation of the patient suspected of having glaucoma.

From the preceding it can be seen that the clinician still has little to help him decide which of his patients with elevated intraocular pressure will advance to frank glaucomatous disease. There are no objective provocative tests that will reliably predict the future. Consequently, one must obtain as much data as possible about an individual patient and, combining all these facts, have either a high or low degree of suspicion. Once a patient is noted to have elevated pressure, however, he must remain a glaucoma suspect, perhaps for the rest of his life. Only the subsequent examination will determine if glaucoma is continuing to be absent (or clinically undetectable) or whether it has actually become clinically manifest. The need for periodic reevaluation is obvious. Careful documentation of the disc, field, and applanation intraocular pressure over a period of time remains the most important aspect of the diagnostic evaluation of the patient with elevated intraocular pressure.     

Schistosome infection among river rafters on Omo River, Ethiopia

BACKGROUND: Adventure trips to Africa have become more frequent, and rafting on some of the great rivers has become almost commonplace. We describe three rafting trips on the Omo River in Ethiopia, after which most of the participants were diagnosed with schistosomiasis. METHODS: After index cases from the three groups came to medical attention, active surveillance detected outbreaks of illness in a group of American travelers (n = 18 ) in 1993 and in two groups of Israeli travelers in 1997 (n = 26). RESULTS: Of 44 travelers, 37 were screened and 28 (76%) were infected, all with Schistosoma mansoni. Among the infected patients, 16 of 28 (57%) were symptomatic, the most frequent manifestation being fever, which occurred in 14 of 25 (56%); cough occurred in 6 of 18 (33%). Diagnosis was based on FAST-enzyme-linked immunosorbent assay, with confirmation by immunoblot. Other rafting trips on the Omo River sponsored by the same tour companies did not result in symptomatic infection. Investigation of the rafting itineraries suggested the route may have been altered from the usual for these three groups, exposing them to a part of the river that is wider, slower moving, and more densely populated. CONCLUSIONS: Schistosomiasis should be considered in febrile patients following rafting trips in schistosome-endemic areas. As asymptomatic schistosomiasis in travelers is also common (43% in this series), all travelers exposed to freshwater in endemic areas should be encouraged to undergo serologic screening.     

Modafinil: new indications for wake promotion

In January 2004, the wake-promoting agent, modafinil, was approved in the US for the treatment of excessive sleepiness (ES) associated with obstructive sleep apnoea/hypopnoea syndrome (OSAHS) and shift-work sleep disorder (SWSD), representing an expansion of its labelling from the initial indication for ES associated with narcolepsy. A total of five randomised, placebo-controlled studies in these three disorders showed statistically significant benefits on various objective measures and subjective estimates of ES, including the Multiple Sleep Latency Test, Maintenance of Wakefulness Test, Epworth Sleepiness Scale and Karolinska Sleepiness Scale. Significant improvement was also seen in overall clinical condition (on the Clinical Global Impression of Change) and measures of sustained attention and reaction time (on the Psychomotor Vigilance Task). The clinical efficacy of modafinil, combined with improved safety over CNS stimulants, has made it the most prescribed medication for the treatment of ES associated with narcolepsy. Modafinil is the only medication approved for ES associated with OSAHS and SWSD (for OSAHS, it is indicated as an adjunct to standard treatments for the under-lying obstruction). Unlike many other medications used for ES, modafinil is not known to be abused. The most common adverse event reported in clinical studies was headaches; most were transient and mild-to-moderate in severity. Modafinil also has the potential for interactions with other drugs metabolised via cytochrome P450 enzyme pathways. Potential obstacles to the use of modafinil include an under-recognition of ES and its consequences. Increased education, both of the public and the medical community, should improve the recognition and therapy of ES.     

Impaired platelet [<Superscript>3</Superscript>H]paroxetine binding in female patients with borderline personality disorder

Rationale There have been few studies of platelet paroxetine binding in borderline personality disorder (BPD). Objective Our aim was to determine whether female BPD subjects show abnormalities in platelet paroxetine binding. Methods Twenty-one female BPD subjects and 16 age- and gender-matched normal control subjects were assessed using the following: (1) Diagnostic Interview for Borderlines, Revised, (2) Diagnostic Assessment for Personality Pathology: Brief Questionnaire, and (3) Barratt Impulsivity Scale. Platelets were collected and assayed for platelet paroxetine binding. Results B _max was lower in the BPD group (p<0.0001), but differences in K _d only reached a trend level. There were no associations with trait dimensions independent of diagnosis. Conclusions Reduced platelet paroxetine binding in female BPD patients may reflect presynaptic serotonin dysfunction. This work was funded by the Medical Research Council of Canada     

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066

BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support (HDC) or intermediate-dose chemotherapy (IDC) in the adjuvant setting. METHODS: Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066. Patients were randomized to receive either high-dose cyclophosphamide, carmustine, and cisplatin (CPA/cDDP/BCNU) and autologous bone marrow transplantation (the HDC arm) or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy (the IDC arm). QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS). RESULTS: At the 3-month assessment, patients in the HDC arm demonstrated significant worsening of QOL compared with the IDC arm in terms of their physical well being (FLIC, P = 0.023), social functioning (FLIC, P = 0.026; PAIS, P < 0.0001), symptom distress (SDS, P = 0.0002), and total QOL scores (FLIC, P = 0.042). At 12 months, the differences in QOL scores between the HDC arm and the IDC arm had resolved. CONCLUSIONS: Patients who received more intensive adjuvant therapy experienced transient declines in QOL. By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline.